GlassScriptPhysician profile
Melanie D Deyoung
NPI 1467406264
$824.44
in general payments reported to CMS, 2019-2025
14 companies · $39.87 in 2025
The $39.87 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.31 · 2022: $191 · 2023: $416 · 2024: $139 · 2025: $39.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405 · Travel and Lodging: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.65 |
| Travel and Lodging | $190.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $231.97 | 2023 | 1688, Spy-Phi System |
| Merck Sharp & Dohme LLC | $200.36 | 2022-2025 | Bridion |
| Baxter Healthcare | $85.43 | 2021-2023 | Seprafilm |
| Boston Scientific Corporation | $56.27 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.58 | 2022-2023 | Trulance |
| Ethicon US, LLC | $36.15 | 2024 | Echelon Endopath |
| Intuitive Surgical, INC. | $25.23 | 2022 | |
| Organogenesis INC. | $23.50 | 2023 | Puraply |
| Takeda Pharmaceuticals U.S.A., INC. | $22.23 | 2023 | Gattex |
| Ferring Pharmaceuticals INC. | $21.74 | 2024 | Rebyota |
| Solventum Corporation | $19.69 | 2024 | V.A.C. Veraflo, Prevena, V.A.C. Dermatac |
| Acacia Pharma INC | $18.32 | 2022 | |
| Access Pro Medical, LLC | $18.08 | 2025 | Matriderm |
| Braintree Laboratories, INC. | $14.89 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Deyoung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.